Olanzapine-samidorphan；
ApprovedSmall molecule
Qilu Pharmaceutical Co., Ltd.Olanzapine-samidorphan； is one of 34 small molecule programs targeting Schizophrenia. It is currently in Approved.
2
Indications
2
Total Trials
2
Active Trials
33
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
583 competitors in Schizophrenia
#DrugCompanyPhaseTrials
1Olanzapine-samidorphan；
Qilu Pharmaceutical Co., Ltd.Approved
Celexa
AbbViePreclinical
Resotran
TakedaPreclinical
Ozempic
Novo NordiskPreclinical
Zocor
OOrganon and Co
Preclinical
Depakote
AbbViePreclinical
Ibrance
PfizerPreclinical
Lunesta
Akero TherapeuticsPreclinical
Comtan
Orion Corporation, Orion PharmaPreclinical
Rapamune
PPrism Pharmaceuticals
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Olanzapine-samidorphan；. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details